CLINICAL TRIALS PROFILE FOR ISAVUCONAZONIUM SULFATE
✉ Email this page to a colleague
All Clinical Trials for isavuconazonium sulfate
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT01813461 ↗ | Study to Evaluate the Pharmacokinetics of 14C-labeled Isavuconazole Following a Single Oral Dose of 14C-labeled Prodrug Isavuconazonium Sulfate (BAL8557) in Healthy Male Subjects | Completed | Basilea Pharmaceutica International Ltd | Phase 1 | 2012-10-01 | The purpose of this study is to evaluate the pharmacokinetics of 14C-labeled isavuconazole and the routes of excretion and the extent of metabolism of 14C-labeled prodrug BAL8557. |
NCT01813461 ↗ | Study to Evaluate the Pharmacokinetics of 14C-labeled Isavuconazole Following a Single Oral Dose of 14C-labeled Prodrug Isavuconazonium Sulfate (BAL8557) in Healthy Male Subjects | Completed | Astellas Pharma Global Development, Inc. | Phase 1 | 2012-10-01 | The purpose of this study is to evaluate the pharmacokinetics of 14C-labeled isavuconazole and the routes of excretion and the extent of metabolism of 14C-labeled prodrug BAL8557. |
NCT02059590 ↗ | A Study to Evaluate the Pharmacokinetics of BAL8728 After a Single Dose of Pyridinylmethyl-14C-Labeled Isavuconazonium Sulfate in Healthy Male Subjects | Completed | Basilea Pharmaceutica International Ltd | Phase 1 | 2013-04-01 | The purpose of this study is to evaluate the pharmacokinetics of 14C-labeled cleavage product (BAL8728), in particular the routes of excretion and extent ot metabolism of the cleavage product following administration of a single intravenous dose of pyridinylmethyl-14C-labeled prodrug isavuconazonium sulfate (BAL8557). In addition, identify the metabolic profile of BAL8728 in human plasma, urine and/or feces after a single intravenous dose of pyridinylmethyl-14C-labeled BAL8557 and evaluate the pharmacokinetics of BAL8728 and BAL4815. Safety and tolerability after a single intravenous dose of pyridinylmethyl-14C-labeled isavuconazonium sulfate will also be evaluated. |
NCT02059590 ↗ | A Study to Evaluate the Pharmacokinetics of BAL8728 After a Single Dose of Pyridinylmethyl-14C-Labeled Isavuconazonium Sulfate in Healthy Male Subjects | Completed | Astellas Pharma Global Development, Inc. | Phase 1 | 2013-04-01 | The purpose of this study is to evaluate the pharmacokinetics of 14C-labeled cleavage product (BAL8728), in particular the routes of excretion and extent ot metabolism of the cleavage product following administration of a single intravenous dose of pyridinylmethyl-14C-labeled prodrug isavuconazonium sulfate (BAL8557). In addition, identify the metabolic profile of BAL8728 in human plasma, urine and/or feces after a single intravenous dose of pyridinylmethyl-14C-labeled BAL8557 and evaluate the pharmacokinetics of BAL8728 and BAL4815. Safety and tolerability after a single intravenous dose of pyridinylmethyl-14C-labeled isavuconazonium sulfate will also be evaluated. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for isavuconazonium sulfate
Condition Name
Condition Name for isavuconazonium sulfate | |
Intervention | Trials |
Healthy Subjects | 3 |
Pharmacokinetics of 14C-labeled Isavuconazonium Sulfate | 1 |
Severe Acute Respiratory Syndrome Coronavirus 2 | 1 |
Aspergillosis Invasive | 1 |
[disabled in preview] | 0 |
This preview shows a limited data set Subscribe for full access, or try a Trial |
Clinical Trial Locations for isavuconazonium sulfate
Trials by Country
Clinical Trial Progress for isavuconazonium sulfate
Clinical Trial Phase
Clinical Trial Sponsors for isavuconazonium sulfate
Sponsor Name